×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BBIO – bridgebio pharma, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BBIO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/12
10:01 pm
bbio
BridgeBio Pharma Touts Attruby Uptake, Bayer's Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf [Yahoo! Finance]
Low
Report
BridgeBio Pharma Touts Attruby Uptake, Bayer's Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf [Yahoo! Finance]
3/12
11:07 am
bbio
BridgeBio Pharma (BBIO) had its "outperform" rating reaffirmed by Leerink Partners.
Low
Report
BridgeBio Pharma (BBIO) had its "outperform" rating reaffirmed by Leerink Partners.
3/11
02:25 pm
bbio
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 [Yahoo! Finance]
Low
Report
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 [Yahoo! Finance]
3/11
02:00 pm
bbio
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
Low
Report
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
3/10
10:01 pm
bbio
BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade [Yahoo! Finance]
Medium
Report
BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade [Yahoo! Finance]
3/10
05:04 pm
bbio
BridgeBio Pharma (BBIO) had its "overweight" rating reaffirmed by Barclays PLC.
Medium
Report
BridgeBio Pharma (BBIO) had its "overweight" rating reaffirmed by Barclays PLC.
3/10
03:37 pm
bbio
BridgeBio Pharma (BBIO) had its price target raised by JPMorgan Chase & Co. from $89.00 to $94.00. They now have an "overweight" rating on the stock.
Low
Report
BridgeBio Pharma (BBIO) had its price target raised by JPMorgan Chase & Co. from $89.00 to $94.00. They now have an "overweight" rating on the stock.
3/10
09:00 am
bbio
BridgeBio Pharma (BBIO) is now covered by William Blair. They set an "outperform" rating on the stock.
High
Report
BridgeBio Pharma (BBIO) is now covered by William Blair. They set an "outperform" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/13
04:23 pm
bbio
Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil
Low
Report
Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil
3/12
04:17 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Mar 10 Filed by: Valantine Hannah
Low
Report
Form 4 BridgeBio Pharma, Inc. For: Mar 10 Filed by: Valantine Hannah
3/10
04:02 pm
bbio
Form 144 BridgeBio Pharma, Inc. Filed by: Valantine Hannah
Medium
Report
Form 144 BridgeBio Pharma, Inc. Filed by: Valantine Hannah
3/6
04:58 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Mar 04 Filed by: Ellis Andrea
Low
Report
Form 4 BridgeBio Pharma, Inc. For: Mar 04 Filed by: Ellis Andrea
3/4
04:18 pm
bbio
Form 144 BridgeBio Pharma, Inc. Filed by: Ellis Andrea
Low
Report
Form 144 BridgeBio Pharma, Inc. Filed by: Ellis Andrea
3/3
04:21 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Feb 27 Filed by: Valantine Hannah
Medium
Report
Form 4 BridgeBio Pharma, Inc. For: Feb 27 Filed by: Valantine Hannah
2/27
04:31 pm
bbio
Form 144 BridgeBio Pharma, Inc. Filed by: Valantine Hannah
Low
Report
Form 144 BridgeBio Pharma, Inc. Filed by: Valantine Hannah
2/27
04:17 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Feb 26 Filed by: Apuli Maricel
Low
Report
Form 4 BridgeBio Pharma, Inc. For: Feb 26 Filed by: Apuli Maricel
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
BridgeBio Pharma (NASDAQ: BBIO) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.
26.9%
12/19 BridgeBio Pharma, Inc. to Present at Upcoming Investor Conference 13.7%
4/3 Form 4 BridgeBio Pharma, Inc. For: Apr 01 Filed by: STEPHENSON BRIAN C 12.4%
10/30 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.6%
11/7 Q3/2019 9/30/2019 EPS -0.510 ZacksConsensus N/A ActVsEst N/A - N/A 10.8%
7/22 BridgeBio Pharma (NASDAQ: BBIO) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating on the stock. 10.3%
4/7 Form 4 BridgeBio Pharma, Inc. For: Apr 03 Filed by: HOMCY CHARLES J 10.3%
12/9 BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs 10.2%
12/18 BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A 10.1%
11/19 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%
12/19 BridgeBio Pharma, Inc. to Present at Upcoming Investor Conference 13.7%
4/3 Form 4 BridgeBio Pharma, Inc. For: Apr 01 Filed by: STEPHENSON BRIAN C 12.4%
10/30 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.6%
11/7 Q3/2019 9/30/2019 EPS -0.510 ZacksConsensus N/A ActVsEst N/A - N/A 10.8%
7/22 BridgeBio Pharma (NASDAQ: BBIO) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating on the stock. 10.3%
4/7 Form 4 BridgeBio Pharma, Inc. For: Apr 03 Filed by: HOMCY CHARLES J 10.3%
12/9 BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs 10.2%
12/18 BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A 10.1%
11/19 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%
TOP News Decliners
3/12
BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations
-16.6%
12/26 Form 8-K BridgeBio Pharma, Inc. For: Nov 07 -14.3%
6/26 Form S-1MEF BridgeBio Pharma, Inc. -10.0%
2/21 BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences -8.0%
9/24 Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options -7.8%
1/10 BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity -7.6%
4/7 Form SEC STAFF LETTER BridgeBio Pharma, Inc. -5.8%
12/24 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -5.5%
12/31 Form 4 BridgeBio Pharma, Inc. For: Dec 27 Filed by: MCCORMICK FRANK -5.2%
3/3 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) -4.7%
12/26 Form 8-K BridgeBio Pharma, Inc. For: Nov 07 -14.3%
6/26 Form S-1MEF BridgeBio Pharma, Inc. -10.0%
2/21 BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences -8.0%
9/24 Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options -7.8%
1/10 BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity -7.6%
4/7 Form SEC STAFF LETTER BridgeBio Pharma, Inc. -5.8%
12/24 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -5.5%
12/31 Form 4 BridgeBio Pharma, Inc. For: Dec 27 Filed by: MCCORMICK FRANK -5.2%
3/3 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) -4.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: